Is NCT04671771 recruiting in New York, NY?

Yes, NCT04671771 is currently recruiting participants at its New York, NY location. This end stage renal disease (esrd) clinical trial is actively enrolling qualified participants.

How do I join the end stage renal disease (esrd) clinical trial in New York?

To join this clinical trial in New York, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this New York clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

End Stage Renal Disease (ESRD) Clinical Trial in New York, NY

About This End Stage Renal Disease (ESRD) Study in New York

The goal of the CSP-2002 clinical trial is to evaluate the safety and effectiveness of the InnAVasc Arteriovenous Graft (IG) for hemodialysis (HD) access in patients with end-stage renal disease (ESRD). The primary study endpoints are: Primary Effectiveness Endpoint: The proportion of subjects with secondary patency at 6 months. Primary Safety Endpoint: The incidence of device-related adverse events of special interest (AESIs) through 6 months. Participants will be asked to sign an informed consent form. Once enrolled, they will be assessed to receive the study graft implant and asked to participate in periodic follow-up visits and assessments through 2 years following implant.

Sponsor: W.L.Gore & Associates

Who Can Participate

Inclusion Criteria

Pre-Operative Inclusion Criteria: Patients must meet the following criteria at screening in order to be scheduled for a procedure and potentially enrolled in the study:

Patients with ESRD whose next most appropriate option for AV access is placement of an AV graft to start or maintain hemodialysis therapy;

Age 18 to 90 years old, inclusive;

Suitable anatomy for implantation of upper arm "straight" or looped graft, or forearm looped graft (graft not to cross the bend of the elbow);

Ability to continue or commence antiplatelet therapy post graft implant (anticoagulation medication is acceptable if the subject is required to take an anticoagulant for a baseline medical condition);

Able and willing to give informed consent;

Anticipated life expectancy of at least 1 year. Intra-Operative Inclusion Criteria: Both vessels have been exposed and are deemed appropriate for implantation (i.e., based on the surgeon's opinion, artery is of adequate size, has adequate pulse to support AV access flow, is without significant calcification, and is safely clampable; and the vein is of adequate size, free of localized sclerosis, and is free of immediate outflow obstruction). Pre-Operative

Exclusion Criteria

Patients will be excluded from the study at screening if they exhibit any of the following exclusion criteria:

History or evidence of severe cardiac disease (i.e., debilitating heart failure, or high risk of MI) in the opinion of the investigator which may preclude participation in and completion of the study;

Uncontrolled diabetes in the opinion of the investigator (i.e., multiple recent diabetes related hospitalizations);

For upper arm straight configuration, an antecubital fossa crease to axillary crease distance \< 18 cm;

History or evidence of severe peripheral arterial disease in the extremity selected for implant (i.e., arterial inflow insufficient to support hemodialysis access);

Known or suspected central vein stenosis or obstruction on the side of planned graft implantation;

Baseline hypotension or history of frequent hypotensive episodes during dialysis that, in the opinion of the investigator, puts the patient at increased risk of graft thrombosis;

Uncontrolled hypertension, per the opinion of the investigator (i.e., recent history of recurrent hospitalizations for hypertensive related illness);

Baseline hemoglobin \<7 g/dL;

Baseline platelet count \<50,000 or \>500,000 cells/mm3;

Documented history of stroke within 6 months prior to enrollment;

Treatment with any investigational drug or device within 30 days prior to enrollment;

Female patients who are pregnant, intending to become pregnant, nursing or intending to breastfeed during the study (pregnancy test may only be omitted, if patient is post-menopausal or has a documented history of hysterectomy or permanent sterilization);

History of cancer with active disease or treatment within the previous year, except for non-invasive basal or squamous cell carcinoma of the skin;

Immunodeficiency including documented history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) or patients receiving immunosuppressive therapy for treatment of an acute inflammatory event or autoimmune flare. Chronic immunosuppressive therapy is acceptable;

Documented or suspected hypercoagulable condition;

Bleeding diathesis, other than that associated with ESRD;

Documented history of heparin-induced thrombocytopenia (HIT);

Active local or systemic infection as documented from the medical history or bloodwork/blood culture data. If the infection resolves, the subject must be at least one-week post resolution of that infection before implantation;

Scheduled renal transplant within 6 months;

Any other condition which in the judgment of the investigator would preclude adequate evaluation of the safety and effectiveness of the IG;

Patient is unable or unwilling to complete all required follow-up assessments and questionnaires.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in New York?

Yes, this clinical trial (NCT04671771) has an active research site in New York, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

End Stage Renal Disease (ESRD) Treatment Options in New York, NY

If you're searching for end stage renal disease (esrd) treatment options in New York, NY, this clinical trial (NCT04671771) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced end stage renal disease (esrd) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all end stage renal disease (esrd) clinical trials near you to find additional studies recruiting in your area.

End Stage Renal Disease (ESRD) Clinical Trial in New York, NY

Expert Care in New York

IRB Approved

No-Cost Care

Apply for This New York Location

Why Participate?

Simple Process